Patient Risk Subgroups Predict Benefit of Adjuvant Chemotherapy in Stage II Rectal Cancer Patients Following Neoadjuvant Chemoradiation and Total Mesorectal Excision
- 26 February 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 20 (3), e155-e164
- https://doi.org/10.1016/j.clcc.2021.02.006
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- NCCN Guidelines Insights: Rectal Cancer, Version 6.2020Journal of the National Comprehensive Cancer Network, 2020
- Nodal staging in rectal cancer: why is restaging after chemoradiation more accurate than primary nodal staging?International Journal of Colorectal Disease, 2016
- Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised studyThe Lancet Oncology, 2014
- Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow-Up of 11 YearsJournal of Clinical Oncology, 2012
- Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC TrialJournal of Clinical Oncology, 2009
- Identification of Patients with High-Risk Stage II Colon Cancer for Adjuvant TherapyDiseases of the Colon & Rectum, 2008
- Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised studyThe Lancet, 2007
- Chemotherapy with Preoperative Radiotherapy in Rectal CancerThe New England Journal of Medicine, 2006
- Preoperative versus Postoperative Chemoradiotherapy for Rectal CancerThe New England Journal of Medicine, 2004
- The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinomaCancer, 1995